Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double‐Blind, Parallel‐Group, R... by Hongjie Chi, Xin Zhang, Shumei Ma, Gang Pan, Xiaojuan Lian, Yan Chen, Haotian Pei, Zichen Liu, Xiangmin Lin

“…Abstract This study aimed to assess the efficacy and safety of a combination therapy of Allisartan Isoproxil 240 mg and Amlodipine 5 mg (ALI/AML) compared to AML 5 mg monotherapy in patients with mild‐to‐moderate essential hypertension. …”
Get full text

Mitochondria-targeted photothermal-chemodynamic therapy enhances checkpoint blockade immunotherapy on colon cancer by Benchao Zheng, Hongbo Wang, Shiyi Zhai, Jiangsheng Li, Kuangda Lu

“…Herein, we constructed a multifunctional nanoplatform that enables mitochondria-targeted photothermal-chemodynamic combination therapy by conjugating indocyanine green-thiol (ICG-SH) and mercaptoethyl-triphenylphosphonium (TPP-SH) onto polyvinyl pyrrolidone (PVP)-coated gold-copper nanoparticles (AIT). …”
Get full text

Early Changes in [18F]FDG Uptake as a Readout for PI3K/Akt/mTOR Targeted Drugs in HER-2-Positive Cancer Xenografts by Yanina Dockx, Christel Vangestel, Tim Van den Wyngaert, Manon Huizing, Sven De Bruycker, Patrick Pauwels, Steven Staelens, Sigrid Stroobants

“…Animals were treated with trastuzumab, everolimus (mTOR inhibitor), PIK90 (PI3K inhibitor), saline, or combination therapy. [18F]FDG scans were performed at baseline, two, and seven days after the start of the therapy. …”
Get full text

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer by Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu

“…Abstract Purpose Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). …”
Get full text

Enhanced effect of radiofrequency ablation on HCC by siRNA-PD-L1-endostatin Co-expression plasmid delivered by Pengfei Chen, Kun Li, Jinwei Chen, He Hei, Jiaxin Geng, Nannan Huang, Mengyu Lei, Huijie Jia, Jianzhuang Ren, Chenwang Jin

“…In this study, an H22 subcutaneous tumor mouse model was used, with animals divided into five groups for treatment with a blank control, a blank Salmonella plasmid, RFA alone, siRNA-PD-L1-endostatin, or a combination of RFA and siRNA-PD-L1-endostatin. The combination therapy significantly reduced tumor growth, angiogenesis, and PD-L1/VEGF expression in tumor tissues post-RFA. …”
Get full text

Targeting sphingosine 1-phosphate receptor 3 inhibits T-cell exhaustion and regulates recruitment of proinflammatory macrophages to improve antitumor efficacy of CAR-T cells agains... by Weiting Liao, Ge Gao, Xia He, Pei Shu, Qizhi Ma, Benxia Zhang, Diyuan Qin, Yongsheng Wang

“…Backgrounds Chimeric antigen receptor (CAR)-modified T cells (CAR-T) are limited in solid tumors due to the hostile tumor microenvironment (TME). Combination therapy could be a promising approach to overcome this obstacle. …”
Get full text

TIGIT inhibitor M6223 as monotherapy or in combination with bintrafusp alfa in patients with advanced solid tumors: a first-in-human, phase 1, dose-escalation trial by Wei Gao, Ping Hu, Aung Naing, Meredith McKean, Anthony Tolcher, Lillian L Siu, Keyvan Tadjalli-Mehr, Anja Victor, Emilia Richter, Marco A F Nogueira Filho, Thomas Kitzing, Stephan Gleicher, Daniel Holland

“…RDEs were 1600 mg every 2 weeks or 2400 mg every 3 weeks for M6223 monotherapy and 1600+1200 mg every 2 weeks for M6223+BA.Conclusions M6223±BA had a manageable safety profile, with RDEs defined for both monotherapy and combination therapy. Further evaluation of M6223 is ongoing in combination with the PD-L1 inhibitor avelumab in patients with advanced urothelial carcinoma (JAVELIN Bladder Medley; NCT05327530).Trial registration number NCT04457778.…”
Get full text

Integrating rapamycin with novel PI3K/Akt/mTOR inhibitor microRNAs on NOTCH1-driven T-cell acute lymphoblastic leukemia (T-ALL) by Fateme Arjmand, Samaneh Shojaei, Mitra Khalili, Hossein Dinmohammadi, Behzad Poopak, Samira Mohammadi-Yeganeh, Yousef Mortazavi

“…Furthermore, in order to evaluate the potential of combination therapy involving miRNAs and rapamycin, apoptosis and cell cycle assays were carried out. …”
Get full text

PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment by Pedro J Romero, Sara Labiano, Gregory Verdeil, Christian Klein, Pablo Umana, Tania Wyss, Christine Trumpfheller, Marie-Catherine Vozenin, Céline Godfroid, Jackeline Romero, Vincent Roh, Genrich V Tolstonog, Chia-Hsien Chuang, Andrea Kelemen, Laura Codarri Deak

“…Importantly, this combination therapy was devoid of measurable toxicity. It induced remodeling of the immune contexture through the increase of CD8+ T and natural killer (NK) cells. …”
Get full text

Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis by Erika Kapp, Jacques Joubert, Samantha L. Sampson, Digby F. Warner, Ronnett Seldon, Audrey Jordaan, Margaretha de Vos, Rajan Sharma, Sarel F. Malan

“…To this end, antimycobacterial activity, mechanism of action, and synergism in combination therapy were investigated for a series of polycyclic amine derivatives. …”
Get full text

A Multifunctional MIL-101-NH2(Fe) Nanoplatform for Synergistic Melanoma Therapy by Shang J, Chen Y, Wang F, Yang J, Li Y, Yang L, Liu X, Zhong Z, Yue C, Zhou M

“…Jinlu Shang,1,2,* Yongjun Chen,2,* Fangliang Wang,3,* Jing Yang,2 Yi Li,4 Liuxuan Yang,2 Xiuqiong Liu,1 Zhirong Zhong,5 Chaochi Yue,6 Meiling Zhou2 1Department of Pharmacy, West China Hospital Sichuan University Jintang Hospital, Chengdu, Sichuan, 610400, People’s Republic of China; 2Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 3Chongqing Key Laboratory for Pharmaceutical Metabolism Research, Chongqing Pharmacodynamic Evaluation Engineering Technology Research Center, College of Pharmacy Chongqing Medical University, Chongqing, 400016, People’s Republic of China; 4Department of Nuclear Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 5Department of Pharmaceutical Sciences, School of Pharmacy, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China; 6Department of Traditional Chinese Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, Sichuan, 646000, People’s Republic of China*These authors contributed equally to this workCorrespondence: Meiling Zhou; Chaochi Yue, Email meilzhou@163.com; yuechaochi18@swmu.edu.cnBackground: Melanoma is an aggressive form of skin cancer, and single-modality treatments often fail to prevent tumor recurrence and metastasis. Combination therapy has emerged as an effective approach to improve treatment outcomes.Methods: In this study, we developed a multifunctional nanoplatform, MIL@DOX@ICG, utilizing MIL-101-NH2(Fe) as a carrier to co-deliver the chemotherapeutic agent doxorubicin (DOX) and the photosensitizer indocyanine green (ICG). …”
Get full text

The Effects of Statin Dose, Lipophilicity, and Combination of Statins plus Ezetimibe on Circulating Oxidized Low-Density Lipoprotein Levels: A Systematic Review and Meta-Analysis o... by Tannaz Jamialahmadi, Fatemeh Baratzadeh, Željko Reiner, Luis E. Simental-Mendía, Suowen Xu, Andrey V. Susekov, Raul D. Santos, Amirhossein Sahebkar

“…There was no difference concerning ox-LDL concentration between treatments with hydrophilic and lipophilic statins (SMD: -0.129, 95% CI: -0.330, -0.071, p=0.206; I2: 45.3%), but there was a significant reduction in circulating concentrations of ox-LDL associated with statin plus ezetimibe combination therapy when compared with statin monotherapy (SMD: -0.220, 95% CI: -0.369, -0.071, p=0.004; I2: 0%). …”
Get full text

Alleviating Tumor Hypoxia and Immunosuppression via Sononeoperfusion: A New Ally for potentiating anti-PD-L1 blockade of solid Tumor by Guoliang Yang, Hui Li, Jiabei Yin, Lei Yao, Jun Yang, Jiawei Tang, You Wu, Meng Zhou, TingTing Luo, Yi Zhang, Jing Zhang, Xuezhi Yang, XiaoXiao Dong, Zheng Liu, Ningshan Li

“…Mechanically, the enhanced efficacy of combination therapy was mainly based on promoting the infiltration and function of CD8+ T cells within tumors. …”
Get full text

Efficacy and safety of acupuncture monotherapy or combined with pelvic floor muscle training for female stress urinary incontinence: a systematic review and meta-analysis by Tong Jiang, Zhi-Yu Dong, Ying Shi, Yang-Qing Zhou, Hong-Bin Zhang, Yi Gong

“…When comparing the group receiving pelvic floor muscle training (PFMT) combined with acupuncture to the PFMT only group, the combination therapy was found to improve urine leakage 1 h (MD = 1.91, 95% CI 0.96 to 2.86, I2 = 80%) and improve ICIQ-SF (MD = 2.63, 95% CI 1.60 to 3.65, I2 = 75%) in patients with SUI, despite significant heterogeneity observed. …”
Get full text

SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway by Yuwen Gong, Dongyang Gao, Yibo Shi, Guangrui Fan, Xiaoquan Yu, Enguang Yang, Hui Cheng, Junqiang Tian, Hui Ding, Shanhui Liu, Shengjun Fu, Yan Tao, Yuan Shui, Liang Cheng, Lanlan Li, Zhiping Wang

“…Altogether, our findings demonstrate that targeting SRC is a promising approach to overcome cisplatin-resistance in bladder cancer, and providing new insights for combination therapy in bladder cancer.…”
Get full text

Drug-drug interaction between ensitrelvir and tacrolimus in a patient undergoing treatment for COVID-19: a case report by Yuki Miyata, Ryo Yamaguchi, Takehito Yamamoto, Toshiyuki Kishida, Kazuhiko Ikeuchi, Hiroaki Harada, Takeya Tsutsumi, Keishi Fujio, Tappei Takada

“…Considering persistent COVID-19, we initiated combination therapy with remdesivir and ensitrelvir (day 0). …”
Get full text

TransferBAN-Syn: a transfer learning-based algorithm for predicting synergistic drug combinations against echinococcosis by Haitao Li, Haitao Li, Yuanyuan Chu, Yuanyuan Chu, Liyuan Jiang, Liyuan Jiang, Lei Li, Lei Li, GuoDong Lv, Yuansheng Liu, Chunhou Zheng, Chunhou Zheng, Yansen Su, Yansen Su

“…Echinococcosis is a zoonotic parasitic disease caused by the larvae of echinococcus tapeworms infesting the human body. Drug combination therapy is highly valued for the treatment of echinococcosis because of its potential to overcome resistance and enhance the response to existing drugs. …”
Get full text

Choice regularities of antihypertensive therapy regimens of primary open-angle glaucoma in conditions of real clinical practice by Z.M. Nagornova, A.V. Seleznev, P.Ch. Zavadskiy, A.V. Kuroyedov

“…<br> <br> <b>Key words:</b> glaucoma, intraocular pressure, beta-adrenoblockers, prostaglandin analogues, combination therapy, therapy regimens.<br> <b>For citation:</b> Nagornova Z.M., Seleznev A.V., Zavadsky P.Ch., Kuroyedov A.V. …”
Get full text

Clinical Characteristics and Optimization of Empirical Antimicrobial Therapy for Febrile Neutropenia in Patients With Hematologic Malignancies by Cui Y, Liu X, Feng S

“…In cases of pneumonia, shock, or suspected carbapenem-resistant infections, combination therapy, tigecycline, and newer antibiotics like ceftazidime/avibactam (CAZ/AVI) are often used. …”
Get full text

Engineered GM-CSF polarizes protumorigenic tumor-associated macrophages to an antitumorigenic phenotype and potently synergizes with IL-12 immunotherapy by Yue Wang, Kevin Chang, Aslan Mansurov, Jun Ishihara, Seounghun Kang, Trevin Kurtanich, Hye Rin Chun, Anna J Slezak, Lisa R Volpatti, Thomas Wang, Aaron T Alpar, Kirsten C Refvik, O Isabella Hansen, Gustavo J Borjas, Brendan T K Berg, Ha-Na Shim, Kevin T Hultgren, Suzana Gomes, Ani Solanki, Melody A Swartz, Jeffrey A Hubbell

“…This resulted in remarkable synergistic efficacy in multiple solid tumor models treated with the dual cytokine combination. The combination therapy also improved the efficacy of CPI in a CPI-resistant genetically-engineered melanoma model and exhibited synergistic antitumor efficacy in a pulmonary metastasis model.Conclusion Our strategy provides a rational design for combination immunotherapy targeting both myeloid and lymphoid compartments through complementary mechanisms.…”
Get full text